SecBot SecBot
PRESS-RELEASE ·Filed Jun 4, 2026

OCUL

Ocular Therapeutix, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The SOL-1 Phase 3 superiority data is the key catalyst to watch at CTS 2026 (June 12-13). Positive efficacy or safety differentiation could drive upside given the 94% bullish analyst consensus and the early-stage biotech stage of Ocular. The HELIOS program update in NPDR may expand the addressable market thesis.

DirectionBullish
Confidencemedium
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$8.80
T+0 close · Jun 4, 2026 · via day close
Latest settled
+17.73%
T+60 · $10.36
Vs SPY
+15.85%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 4 $8.80entry
  2. T+1 · 6mo ago −6.25%α −3.65% · $8.25
  3. T+5 · 5mo ago −1.14%α +1.42% · $8.70
  4. T+20 · 4mo ago +9.55%α +10.92% · $9.64
  5. T+60 · 3mo ago +17.73%α +15.85% · $10.36
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ocular Therapeutix announced its participation at Clinical Trials at the Summit 2026, where it will present multiple data updates on AXPAXLI (OTX-TKI) including results from the SOL-1 Phase 3 superiority trial in wet AMD and a HELIOS program update in NPDR. The conference presentations are scheduled for June 12-13, 2026, in Las Vegas, with a CEO fireside chat and several clinical sessions.

Key Facts

  • SOL-1 Phase 3 superiority trial efficacy outcomes with OTX-TKI in neovascular AMD to be presented at CTS 2026 on June 13
  • HELIOS program update on OTX-TKI in nonproliferative diabetic retinopathy (NPDR) also scheduled for June 13
  • Safety and tolerability profile of OTX-TKI in neovascular AMD presented separately on the same day
  • Pravin U. Dugel, MD (CEO) participating in fireside chat 'From Global KOL to CEO' and panel 'From Innovation to Approval'
  • AXPAXLI (OTX-TKI) is an axitinib intravitreal hydrogel based on ELUTYX bioresorbable hydrogel technology, currently in Phase 3 for wet AMD and diabetic retinal disease

Financial Impact

No financial data disclosed; presentations focus on clinical trial results for AXPAXLI. Positive SOL-1 data could support regulatory filings and enhance pipeline value for a $1.8B market cap biotech.

pipeline valueapproval probability

Risk Factors

  • SOL-1 Phase 3 data may fail to show superiority vs. existing anti-VEGF standard of care
  • Competitive pressure from faricimab and other long-acting agents in wet AMD

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3306630

Track record

20 reports on OCUL

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +24.88% at T+20 after the Aug 3, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 10, 20266d ago 3 Neutral 2/10 Entry $6.66 Now $6.01 −9.76% settles Nov 18
  2. Nov 9, 20267d ago 8-K Neutral 2/10 Entry $6.85 to $6.01 Now $6.01 −12.26% ▼ −12.26% −10.57% vs SPY
  3. Nov 9, 20267d ago Press Release Bearish 5/10 Entry $6.85 to $6.01 Now $6.01 +12.26% ▲ +12.26% +10.57% vs SPY
  4. Nov 5, 202611d ago 144 Neutral 3/10 Entry $6.60 to $6.21 Now $6.01 −8.87% ▼ −5.84% −8.43% vs SPY
  5. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.29 to $6.47 Now $6.01 −4.45% ▲ +2.86% +3.01% vs SPY
  6. Oct 8, 20265w ago 144 Neutral 2/10 Entry $7.54 to $6.87 Now $6.01 −20.29% ▼ −8.89% −6.92% vs SPY
  7. Sep 2, 202610w ago Insider Cluster Neutral 4/10 Entry $10.64 to $10.49 Now $6.01 −43.52% ▼ −1.41% −0.26% vs SPY
  8. Aug 26, 202611w ago Insider Cluster Neutral 3/10 Entry $10.82 to $10.64 Now $6.01 −44.45% ▼ −1.66% −1.93% vs SPY
  9. Aug 3, 202615w ago 8-K Bullish 7/10 Entry $8.40 to $9.24 Now $6.01 −28.45% ▲ +10.00% +7.97% vs SPY
  10. Jun 17, 202621w ago Press Release Bullish 6/10 Entry $9.64 to $9.85 Now $6.01 −37.66% ▲ +2.18% +3.22% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 8h 53m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 4, 2026